5326122025-04-012025-06-305326122025-04-012025-06-30in-capmkt:OtherExpenses1Member5326122025-04-012025-06-30in-capmkt:OtherExpenses2Member5326122025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15326122025-04-012025-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares532612INDOCONOTLISTEDINE873D01024INDOCO REMEDIES LIMITEDMain BoardEquity2025-04-012026-03-312025-07-242025-07-14INRLakhsQuarterlyFirst quarterSingle segmentPharmaceutical2025-07-2410:30:002025-07-2411:50:002025-04-012025-06-30UnauditedConsolidated43789000001630000043952000001055300000392300000-97900000107020000026120000029700000017837000004761800000-3666000000-3666000000-3100000-31000000-3635000000000-363500000-1600000-365100000-357900000-5600000-359500000-56000001845000002-3.94-3.9400-3.94-3.941. The unaudited Consolidated Results for the Quarter ended 30th June, 2025, have been reviewed by the Audit committee and approved by the Board of Directors of the Company at its meeting held on 24th July, 2025. The Statutory Auditors have expressed an Unmodified Audit opinion on these unaudited Consolidated Financial Results. <BR> <BR> 2. The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. <BR> <BR> 3. The company has only one primary reportable segment of activity, namely, Pharmaceuticals. <BR> <BR> 4. Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows: <BR> <BR> Net Sales Qtr ended Qtr ended Qtr ended Year ended <BR> & Income 30-06-2025 31-03-2025 30-06-2024 31-03-2025 <BR> from Operations (Unaudited) (Audited) (Unaudited) (Audited) <BR> <BR> India 27,783 26,186 25,675 1,09,039 <BR> Outside India 15,125 12,203 16,754 55,090 --------------------------------------------------------------------------------------------------------------------------- <BR> Total : 42,908 38,389 42,429 1,64,129============================================================== <BR> <BR> 5. The Consolidated Financial Results includes the results of the following companies. <BR> ----------------------------------------------------------------------------------------------------------------------------- <BR> Name of the Company % of shareholding Consolidated as <BR> ------------------------------------------------------------------------------------------------------------------------------ <BR> XTEND INDUSTRIAL DESIGNERS 100.00 SUBSIDIARY <BR> & ENGINEERS PVT LTD <BR> INDOCO REMEDIES CZECH SRO 100.00 SUBSIDIARY <BR> INDOCO REMEDIES UK LTD 100.00 SUBSIDIARY <BR> WARREN REMEDIES PVT LTD 100.00 SUBSIDIARY <BR> FPP HOLDING COMPANY ,LLC 85.00 SUBSIDIARY <BR> -------------------------------------------------------------------------------------------------------------------------- <BR> <BR> 6. Figures for the quarter ended 31.3.2025 and 31.3.2024 represents the difference between audited figures in respect of the full financial year and published figures for the period ended 31.12.2024 (limited reviewed) and 31.12.2023 (limited reviewed). <BR> <BR> 7. (*) Exceptional items include consideration received Rs. 99.4 lacs for grants to use exclusive, perpetual and irrevocable license rights in respect of trademarks of the company. <BR> RESEARCH & DEVELOPMENT EXPENSES216600000OTHER EXPENSES1567100000Items that will not be reclassified to profit & loss-7700000-7700000-1900000Items that may be reclassified to profit or loss870000087000004500000-1600000